miR‐31‐3p and colorectal cancer
The miRpredX 31-3p test predicts clinical response to anti-EGFR therapy in RAS wild type patients with metastatic colorectal cancer assisting clinicians to identify the most appropriate therapeutic strategy when combining information on miRNA miR-31-3p expression with other molecular and patient factors which influence patient outcomes.
miR-31-3p presentation and publications
Studies demonstrating the association between miR-31-3p and survival in metastatic colorectal cancer have been published in peer-reviewed journals and presented at numerous scientific meetings.
IntegraGen's scientific advisory board for metastatic colorectal cancer includes world renown clinicians who represent both academic and community oncology. Our advisers provide us with valued insight and guidance on our efforts to develop oncology biomarkers which assist physicians to better manage cancer patients.
What are microRNA’s?